At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
MEDI0382 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating MEDI0382 and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 65 participants across 5 sites.
Detailed Summary
A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM). Approximately 63 subjects will be enrolled across two cohorts.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionJan 2018
TodayJul 2026
First PostedAug 10, 2017
Enrollment StartSep 4, 2017
Primary CompletionJan 23, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.9 years ago
Interventions
MEDI0382drug
MEDI0382 will be administered subcutaneously once daily for 49 days.
Placebodrug
Placebo will be administered subcutaneously once daily for 49 days.